Pfizer loses appeal to revive patent
- Share via
Pfizer Inc. lost an appeals court bid to revive its patent on the hypertension drug Norvasc, a ruling that opened the door to generic competition.
The U.S. Court of Appeals for the Federal Circuit in Washington denied Pfizer’s request to reconsider a March 22 ruling that the patent was invalid.
The March ruling allowed Mylan Laboratories Inc. to make a generic version of Norvasc. Apotex Inc., the Canadian drug maker that won the lawsuit over the patent’s validity, also may enter the market as early as today.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
